Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The ELIXA trial examined once-daily lixisenatide (not available in Australia) in a population with a recent myocardial infarction or recent hospitalisation for unstable angina
3.4 Glucoselipid metabolism and IR Insulin resistance serves as the crucial hub connecting metabolic derangements and reproductive dysfunction in PCOS, making it a primary target for GLP-1RA intervention within the metabolicreproductive axis
In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more
Fluids Barriers CNS 21 (1), 2
Nausea, vomiting, and constipation are the most common tolerability issues, and combining two appetite-suppressing agents can compound them
US$ 25.53
US$ 26.63
US$ 25.95
US$ 29.84
US$ 23.46
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 29.81
US$ 22.59
